retatrutide clinical trial results 2024 2025 press release Lilly's triple agonist delivers up to 71.2 lbs of weight loss Eli Lilly Obesity Wins Recast
Description
& Brubaker, P
the 2023 SELECT trial), have fueled surging global demand
For non-diabetics with obesity, first line treatment is lifestyle changes
Eli Lilly has produced medications such as: Mounjaro, Zepbound and Orgforglipron
